Company / Gross Margin
ENDONOVO THERAPEUTICS, INC. Gross Margin History
FY2014-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
92.6%
FY2022
5-year range
60.6% / 92.6%
FY2018-FY2022
Trend
+16.5%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from 60.6% to 92.6% over the past 2 years.
Based on SEC 10-K filings.
92.6% in FY2022 with a 3-year CAGR of +22.7%.
Improved from 60.6% to 92.6% over the past 2 years.
Gross Margin over time
Growth rates
- 3-Year Change
- +22.7pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2022, gross margin increased 16.5% year-over-year.
- Lowest gross margin in the period was in FY2014.
Company context
Key Data Points
- Altman Z-Score -76.54 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | 92.6% | +16.5% |
| FY2021 | 79.5% | +31.3% |
| FY2020 | 60.6% | -13.3% |
| FY2019 | 69.9% | -17.3% |
| FY2018 | 84.5% | - |
| FY2016 | - | - |
| FY2015 | 49.3% | +37.0% |
| FY2014 | 36.0% | - |
| FY2011 | - | - |
As of FY2022 · SEC 10-K · Updated Jun 29, 2026